BR112021019050A2 - Composto derivado de azaindol, composição farmacêutica, inibidor de csf-1r e agente anticâncer que compreendem o dito composto, usos do composto para fabricar o inibidor e agente, bem como usos terapêuticos do dito composto - Google Patents

Composto derivado de azaindol, composição farmacêutica, inibidor de csf-1r e agente anticâncer que compreendem o dito composto, usos do composto para fabricar o inibidor e agente, bem como usos terapêuticos do dito composto

Info

Publication number
BR112021019050A2
BR112021019050A2 BR112021019050A BR112021019050A BR112021019050A2 BR 112021019050 A2 BR112021019050 A2 BR 112021019050A2 BR 112021019050 A BR112021019050 A BR 112021019050A BR 112021019050 A BR112021019050 A BR 112021019050A BR 112021019050 A2 BR112021019050 A2 BR 112021019050A2
Authority
BR
Brazil
Prior art keywords
compound
inhibitor
agent
csf
manufacture
Prior art date
Application number
BR112021019050A
Other languages
English (en)
Inventor
Akira Iwata
Ayumu Okuda
Gen Watanabe
Hirotaka Sasaki
Hiroyuki Ishiwata
Keigo Nishii
Kosuke Usuda
Takahisa Ogamino
Toshiharu Morimoto
Yuichiro Tabunoki
Original Assignee
Kowa Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co filed Critical Kowa Co
Publication of BR112021019050A2 publication Critical patent/BR112021019050A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

composto derivado de azaindol, composição farmacêutica, inibidor de csf-1r e agente anticâncer que compreendem o dito composto, usos do composto para fabricar o inibidor e agente, bem como usos terapêuticos do dito composto. a presente invenção fornece um novo composto ou um sal do mesmo ou um solvato do mesmo, tendo uma atividade inibitória de csf-1r e apresentando efeito antitumoral. um derivado de azaindol de fórmula (i): em que a representa um anel c6-10 aril, um heterociclo aromático ou um heterociclo insaturado, e a opcionalmente tem um substituinte ou mais substituintes iguais ou diferentes; e r representa um grupo c1-3 alquil ou um grupo heterocíclico saturado, ou um sal do mesmo ou um solvato do mesmo.
BR112021019050A 2019-03-29 2020-03-30 Composto derivado de azaindol, composição farmacêutica, inibidor de csf-1r e agente anticâncer que compreendem o dito composto, usos do composto para fabricar o inibidor e agente, bem como usos terapêuticos do dito composto BR112021019050A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019068233 2019-03-29
PCT/JP2020/014475 WO2020203950A1 (ja) 2019-03-29 2020-03-30 新規アザインドール誘導体

Publications (1)

Publication Number Publication Date
BR112021019050A2 true BR112021019050A2 (pt) 2021-11-30

Family

ID=72668977

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021019050A BR112021019050A2 (pt) 2019-03-29 2020-03-30 Composto derivado de azaindol, composição farmacêutica, inibidor de csf-1r e agente anticâncer que compreendem o dito composto, usos do composto para fabricar o inibidor e agente, bem como usos terapêuticos do dito composto

Country Status (10)

Country Link
US (1) US20220162206A1 (pt)
EP (1) EP3950063A4 (pt)
JP (1) JPWO2020203950A1 (pt)
KR (1) KR20210146320A (pt)
CN (1) CN113613729A (pt)
BR (1) BR112021019050A2 (pt)
CA (1) CA3134937A1 (pt)
MX (1) MX2021011923A (pt)
SG (1) SG11202109997PA (pt)
WO (1) WO2020203950A1 (pt)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288918A (en) * 1992-09-29 1994-02-22 Union Carbide Chemicals & Plastics Technology Corporation Hydroformylation process
US5767321A (en) * 1995-12-06 1998-06-16 Union Carbide Chemicals & Plastics Technology Corporation Metal-ligand complex catalyzed processes
DK1696920T3 (en) * 2003-12-19 2015-01-19 Plexxikon Inc RELATIONS AND PROCEDURES FOR THE DEVELOPMENT OF LAW MODULATORS
CA2570817A1 (en) 2004-06-17 2006-01-26 Plexxikon, Inc. Azaindoles modulating c-kit activity and uses therefor
WO2008063888A2 (en) * 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
EP2241333A1 (en) 2007-12-12 2010-10-20 National Cancer Center Therapeutic agent for mll leukemia and moz leukemia of which molecular target is m-csf receptor, and use thereof
MX2012010014A (es) 2010-03-05 2012-09-21 Hoffmann La Roche Anticuerpos contra csf-1r humano y sus usos.
US9358235B2 (en) * 2012-03-19 2016-06-07 Plexxikon Inc. Kinase modulation, and indications therefor
AU2015334915B2 (en) * 2014-10-23 2019-09-19 Janssen Pharmaceutica Nv New pyrazolopyrimidine derivatives as NIK inhibitors
MY186368A (en) * 2015-07-20 2021-07-16 Genzyme Corp Colony stimulating factor-1 receptor (csf-1r) inhibitors
US20200071326A1 (en) * 2017-04-14 2020-03-05 Syros Pharmaceuticals, Inc. Tam kinase inhibitors

Also Published As

Publication number Publication date
JPWO2020203950A1 (pt) 2020-10-08
MX2021011923A (es) 2021-11-03
SG11202109997PA (en) 2021-10-28
WO2020203950A1 (ja) 2020-10-08
CA3134937A1 (en) 2020-10-08
EP3950063A1 (en) 2022-02-09
EP3950063A4 (en) 2022-11-30
CN113613729A (zh) 2021-11-05
KR20210146320A (ko) 2021-12-03
US20220162206A1 (en) 2022-05-26

Similar Documents

Publication Publication Date Title
BR112019000247A2 (pt) derivados de 1,3-di-hidróxi-fenila úteis como imunomoduladores
DOP2018000222A (es) Inhibidores de mcl1 macrocíclicos para tratar el cáncer antecedentes
ECSP15035343A (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida útiles como inhibidores de quinasa pim
NI201500120A (es) Compuestos de biaril - amida como inhibidores de cinasa
BR112014025564A8 (pt) composto heterocíclico contendo nitrogênio ou sal do mesmo
UY37900A (es) Nuevos derivados de rapamicina
AR104513A1 (es) Derivados de ciclohexano sustituidos con amidas como inhibidores de tnks1 y/o tnks2
NI201700029A (es) Compuestos y composiciones como inhibidores de quinasa raf.
AR085960A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
UY30804A1 (es) Derivados de nicotinamida, sus sales y solvatos, composiciones farmacéuticas conteniendolas y aplicaciones
BR112017020467A2 (pt) derivado de metil mentol e composição de agente refrescante contendo o mesmo
AR100049A1 (es) Derivados de dihidrotiazina y dihidrooxazina con actividad inhibidora de bace1
DOP2024000039A (es) Derivados de quinolina como inhibidores de la integrina alfa4beta7
BR112012004851B8 (pt) uso de um derivado de tiazol
BR112015022385A2 (pt) droga para uma doença respiratória
BR112016013618A8 (pt) derivados de maleimida como moduladores de série de reação de wnt, seus usos, composição farmacêutica e processo para a preparação dos mesmos
BR112022001922A2 (pt) Compostos de heteroarila de anel fundido como inibidores de ripk1
CL2021002946A1 (es) Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1
CO2022015157A2 (es) Compuestos y composiciones para inhibir la actividad de hif2-alfa y sus métodos de uso
CL2022001741A1 (es) Compuestos cíclicos y métodos de uso de estos
BRPI0619838A8 (pt) composições fungicidas e derivado de amida de ácido carboxílico
BR112013024497A2 (pt) novo derivado de oxazolidinona e composição farmacêutica incluindo o mesmo
BR112021019050A2 (pt) Composto derivado de azaindol, composição farmacêutica, inibidor de csf-1r e agente anticâncer que compreendem o dito composto, usos do composto para fabricar o inibidor e agente, bem como usos terapêuticos do dito composto
MX362192B (es) Derivado de glicinamida alfa-sustituida.
PE20211454A1 (es) Derivados de imidazopiridina y su uso como medicamento

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]